(Boursier.com) — Abionyx Pharmaa next-generation biotech company dedicated to the discovery and development of innovative therapies, today provides an update on its activity and its cash position.
The group publishes a consolidated turnover for 2022 of 5.3 ME net of studies for Abionyx.
Cash stood at €4 million as of December 31, 2022.
The announcement of the biotech strategy in ophthalmology is scheduled for March 2023.
©2023 Boursier.com